

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1998

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

FOR THE TRANSITION PERIOD FROM _____ TO _____

COMMISSION FILE NUMBER: 000-23-661

ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of small business issuer as specified in its charter)

MICHIGAN 38 -3317208

(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)

28025 OAKLAND OAKS DRIVE
WIXOM, MICHIGAN 48393

(Address of principal executive offices)

Issuer's telephone number (248) 449-3353

(NONE)

(Former name, former address and former fiscal year, if changed since last
report)

Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes No

State the number of shares outstanding of each of the issuer's classes of
common equity as of the latest practicable date: 4,830,450 Common Shares
outstanding and 3,625,000 Common Share Purchase Warrants outstanding as of May
8, 1998.

Transitional Small Business Disclosure Format (Check one):
Yes No

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
(WHOLE DOLLARS)
(Unaudited)

JUNE 30, 1998

ASSETS	-----
Cash and Cash Item	\$ 2,527,749
Accounts Receivable, net of allowance for doubtful accounts of \$26,000 ..	574,570
Inventory	301,099
Other Current Assets	70,729

TOTAL CURRENT ASSETS	3,474,147
Property and Equipment, net	880,814
Other Noncurrent Assets	177,937
Excess of Purchase Price over Fair Value of Net Assets Acquired, net	1,353,502

TOTAL ASSETS	\$ 5,886,400
	=====
LIABILITIES AND SHAREHOLDERS' EQUITY	
Accounts Payable	\$ 450,509
Accrued Liabilities	125,173

TOTAL CURRENT LIABILITIES	575,682
SHAREHOLDERS' EQUITY:	
Common Shares, no par value, 4,830,450 shares issued and outstanding	8,055,823
Common Share Purchase Warrants, 3,625,000 warrants issued and outstanding	251,150
Deficit	(2,996,255)

	5,310,718

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 5,886,400
	=====

The accompanying notes are an integral part of the consolidated financial statements.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY

CONSOLIDATED INCOME STATEMENT
(WHOLE DOLLARS)
(Unaudited)

	THREE MONTHS ENDED JUNE 30, 1998 -----	THREE MONTHS ENDED JUNE 30, 1997 -----	SIX MONTHS ENDED JUNE 30, 1998 -----	SIX MONTHS ENDED JUNE 30, 1997 -----
SALES	\$ 1,180,130	\$ 812,549	\$ 2,153,289	\$ 1,151,401
Cost of Sales	1,292,579	1,042,482	2,427,157	1,469,938
	-----	-----	-----	-----
GROSS DEFICIT	(112,449)	(229,933)	(273,868)	(318,537)
Selling, General and Administrative.....	447,671	310,004	836,944	570,216
	-----	-----	-----	-----
OPERATING LOSS	(560,120)	(539,937)	(1,110,812)	(888,753)
Interest Income (Expense), net	17,384	(38,207)	28,491	(54,427)
	-----	-----	-----	-----
NET LOSS	\$ (542,736)	\$ (578,144)	\$(1,082,321)	\$ (943,180)
	=====	=====	=====	=====
Average shares outstanding	4,859,794	2,793,602	4,600,712	2,767,583
BASIC AND DILUTED LOSS PER SHARE	\$ (.11)	\$ (.20)	\$ (.24)	\$ (.34)

The accompanying notes are an integral part of the consolidated financial statements.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30
(WHOLE DOLLARS)
(Unaudited)

	1998	1997
	-----	-----
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$(1,082,321)	\$ (943,181)
Adjustments to reconcile net loss to net cash used for operating activities:		
Depreciation and Amortization	169,906	122,371
	-----	-----
	(912,415)	(820,810)
Changes in Working Capital:		
Increase in Accounts Receivable	(187,305)	(100,150)
Increase in Inventory	(7,380)	(47,629)
Increase in Other Current Assets	(14,294)	(71,615)
Decrease in Accounts Payable	(587,326)	(157,732)
Increase (Decrease) in Other Liabilities	(357,675)	81,968
	-----	-----
Net change in Working Capital	(1,153,980)	(295,158)
NET CASH USED IN OPERATIONS	(2,066,395)	(1,115,968)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of Business, net of cash acquired	--	(508,887)
Purchase of Equipment	(267,138)	(23,472)
Redemption (Purchase) of Certificate of Deposit	25,000	(25,000)
	-----	-----
CASH USED IN INVESTING ACTIVITIES	(242,138)	(557,359)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Issuance of Common Shares	5,982,064	2,441,297
Issuance of Common Share Purchase Warrants	251,150	--
Purchase of Common Shares	(164,359)	--
Proceeds from notes payable - shareholders	--	125,000
Payment on promissory note	--	(500,000)
Repayment of notes payable	(200,000)	(125,000)
Redemption of Series A Preferred Stock	(1,095,915)	--
Deposits paid on leases.....	--	(138,397)
	-----	-----
CASH PROVIDED BY FINANCING ACTIVITIES	4,772,940	1,802,900
INCREASE IN CASH	2,464,407	129,573
CASH AT BEGINNING OF PERIOD	63,342	--
	-----	-----
CASH AT END OF PERIOD	\$ 2,527,749	\$ 129,573
	=====	=====

Interest paid upon the redemption of the Series A Preferred Stock was \$62,272.

The accompanying notes are an integral part of the consolidated financial statements.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. ORGANIZATION AND CAPITALIZATION

Rockwell Medical Technologies, Inc. (the "Company") was incorporated on October 25, 1996 for the purpose of purchasing and operating the business of Rockwell Medical Supplies, L.L.C. and its sister company, Rockwell Transportation, L.L.C. (collectively, the "Predecessor Companies"). The Company is, and the Predecessor Companies were, in the business of manufacturing and distributing hemodialysis concentrates and dialysis kits to hemodialysis clinics. The Company also packages, sells and distributes ancillary products related to the hemodialysis process, as did the Predecessor Companies.

The Company is regulated by the Federal Food and Drug Administration under the Federal Drug and Cosmetics Act, as well as by other federal, state and local agencies. In March 1996 the Predecessor Companies received 510(k) approval from the FDA to market hemodialysis solutions and powders, which commenced in May 1996. The 510(k) approval was assigned to the Company in connection with the purchase of the Predecessor Companies.

Effective February 19, 1997 the Company purchased the assets and assumed certain liabilities of the Predecessor Companies for an initial purchase price of approximately \$2.4 million, excluding liabilities assumed. The transaction was accounted for using the purchase method of accounting. The initial purchase price was allocated to assets acquired and liabilities assumed based on the estimated fair market value at the date of acquisition.

Effective January 26, 1998 the Company issued 1,800,000 Common Shares and 3,105,000 Common Share Purchase Warrants pursuant to a Registration Statement filed with the Securities and Exchange Commission. The offering price was \$4.00 per share for the Common Shares and \$.10 per warrant for the Common Share Purchase Warrants. Net proceeds from this offering were approximately \$5.9 million. Proceeds were used to redeem the Series A Preferred Shares, repay the Notes Payable and reduce Accounts Payable and accrued expenses. The balance of the funds was invested in short-term cash investments.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The consolidated financial statements of the Company include the accounts of Rockwell Medical Technologies, Inc. and its wholly owned subsidiary, Rockwell Transportation, Inc. All intercompany balances and transactions have been eliminated. The results of operations and cash flows are presented from October 25, 1996 (the date of inception) through June 30, 1997 and January 1, 1998 through June 30, 1998. During the period October 25, 1996 through December 31, 1996 the Company incurred and accrued expenses of \$49 thousand, primarily consulting fees, in conjunction with the initial organization of the Company.

In the opinion of management, all necessary adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The operating results for the six month period ended June 30, 1998 are not necessarily indicative of the results to be expected for the year ending December 31, 1998.

2. BASIS OF PRESENTATION (CONT'D)

COMPREHENSIVE INCOME

A Statement of Comprehensive Income for the periods ended June 30, 1998 and 1997 is not presented in accordance with Statement of Financial Accounting Standard No. 130 as the Company has no Comprehensive Income.

3. INVENTORY

Components of inventory are as follows:

Raw Materials.....	\$	210,856
Finished Goods.....		90,243

Total	\$	301,099
		=====

4. RELATED PARTY TRANSACTIONS

In July 1997, the Company obtained a demand loan from Karen Bagley in the amount of \$100,000 and in November 1997 the Company obtained a loan from Michael J. Xirinachs in the amount of \$100,000 due February 11, 1998. The loans bear interest at an annual rate of 24%. These loans were repaid in January and February 1998 with the proceeds of the Initial Public Offering. Karen Bagley is the wife of Patrick Bagley, whose firm serves as legal counsel to the Company on certain matters and also to Mr. Robert L. Chioini in a personal capacity. Michael J. Xirinachs is a founder and a Director of the Company.

During each of the six month periods ended June 30, 1997 and 1998, the Company paid fees to the consulting firm of Wall Street Partners, Inc. for financial and management services of \$150,000. The principals of the consulting firm are shareholders of the Company and members of the Board of Directors.

ITEM 6. MANAGEMENT'S DISCUSSIONS AND ANALYSIS OR PLAN OF OPERATION.

RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 1998 AND 1997

Financial results for the period ended June 30, 1997 include the results of operations of the Company from the purchase of the Predecessor Company on February 19, 1997 through June 30, 1997. Sales for the six months ended June 30, 1998 and 1997 were \$2,153.3 thousand and \$1,115.4 thousand respectively, an increase of 45% after adjusting for the short period of operating results in 1997.

Product line sales of acid concentrate increased 47%, bicarbonate powder sales increased 129%, and the ancillary product lines were comparable in the six month period ended June 30, 1998 as compared to the same period in 1997 after adjusting prior year's sales for the short period of operations. Sales of the acid concentrate reflect increased market penetration by the Company primarily due to a new customers attained in mid 1997 and March 1998. Bicarbonate powder sales partially increased as a result of the inability of a competitor to manufacture a liquid bicarbonate. Clinics substituted the Company's powder formulation for our competitors' product. In addition to the Company's main product lines of acid concentrate, powdered bicarbonate and ancillary products, the six month period ended June 30, 1997 included sales of \$236.6 thousand of acetate, a product used for hemodialysis in certain South American countries. There were no sales of acetate in 1998.

Gross margin before distribution costs was \$289.2 thousand, 13% of sales, in the period ended June 30, 1998 compared to a deficit of (\$58.0) thousand in the same period in 1997. Production efficiencies, lower material costs, and greater volume contributed to this positive margin in 1998. Distribution expense, net of backhaul revenue, was \$563.1 thousand or 26% of sales in period ended June 30, 1998. This is comparable to the 1997 period in which distribution expenses was 27% of sales.

Selling, General and Administrative expense were comparable as a percent of sales for the six months ended June 30, 1997 as compared to the six months ended June 30, 1998. The gross increase in Selling, General and Administrative costs was \$266.7 thousand of additional cost in 1998 as compared to 1997. Costs in the 1998 period, for which no expense was recorded in 1997, include compensation expense associated with the Company's stock option plan of \$53 thousand and investor relation and other costs associated with public company requirements of approximately \$64.5 thousand. Other cost increases of approximately \$147.3 thousand were related to salaries, wages, and employee benefits.

Basic and fully diluted loss per share improved to (\$.24) for the period ended June 30, 1998 from a loss per share of (\$.34) for the comparable period in 1997. Although the net loss of the company increased to \$(1,082.3) thousand in the six months ended June 30, 1998 as compared to \$(943.2) thousand in the period February 19 through June 30, 1997, the loss per share improved as a result of the increased average shares outstanding. The increased average shares outstanding was directly attributable to the additional Common Shares issued in conjunction with the Initial Public Offering.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 1998 AND 1997

Sales for the three month period ended June 30, 1998 were \$1,180.1 thousand as compared to \$812.5 thousand in the comparable period of 1997. The increase in sales is attributable to the factors discussed in the RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 1998 AND 1997 above. This increase is partially offset by the sale of acetate which occurred during the three month period ended June 30, 1997 as is noted in the discussion above.

The increase in the Operating Loss from \$(539.9) thousand in the three months ended June 30, 1997 as compared to \$(560.1) thousand in the comparable period in 1998 was the result of an improvement in the costs of production offset by increased Selling, General and Administrative Expense. The causal factors associated with these variances are the same as those discussed in the RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 1998 AND 1997 above.

LIQUIDITY AND CAPITAL RESOURCES

The Company issued 1,800,000 Common Shares and 3,105,000 Common Share Purchase Warrants pursuant to a Registration Statement filed with the Securities and Exchange Commission on January 26, 1998 (the "IPO"). Net IPO proceeds of \$5.9 million were used for: (a) payments for redemption of the Series A Preferred Shares (\$1.1 million), (b) payments of accounts payable and certain liabilities (\$700 thousand), and (c) repayment of promissory notes (\$217 thousand). The balance of the cash remaining, approximately \$3.9 million, will be used to fund operating cash needs and capital equipment and expansion programs.

Operating cash requirements, excluding working capital needs were \$912.4 thousand for the six months ended June 30, 1998. In addition working capital requirements, primarily accounts receivable caused by the growth in revenue, was approximately \$254 thousand. The Company anticipates that these cash needs will continue in the future as our growth strategy is implemented.

Capital equipment purchases were \$267.1 thousand for the six month period ended June 30, 1998. This capital was primarily related to technological improvements in existing manufacturing processes and other expenditures to enable the company to manufacture the new product, Sterilyte(TM) Liquid Bicarbonate.

The Company also used cash to repurchase 108,300 Common Shares for approximately \$164 thousand during the first six months of 1998.

PART II - OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

Exhibit No	Description
-----	-----
27.1	Financial Data Schedule
27.2	Financial Data Schedule
27.3	Financial Data Schedule
27.4	Financial Data Schedule

(b) Reports on Form 8-K
(None)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Registrant)

Date August 13, 1998

/s/ ROBERT L. CHIOINI

Robert L. Chioini
President, Chief Executive
Officer and Director (Principal
Executive Officer)

Date August 13, 1998

/s/ JAMES J. CONNOR

James J. Connor
Vice President of Finance, Chief
Financial Officer, Treasurer and
Secretary (Principal Financial
Officer and Principal Accounting
Officer)

Exhibit Index

Exhibit No	Description
-----	-----
27.1	Financial Data Schedule
27.2	Financial Data Schedule
27.3	Financial Data Schedule
27.4	Financial Data Schedule

3-MOS

	DEC-31-1998	APR-01-1998	JUN-30-1998
			0
		0	
		0	
		0	
	0		
		0	0
		0	
	0		
	0		
			0
			0
		0	
		0	
0			
	1,180,130		
	1,180,130		
		1,292,579	
	1,292,579		
	447,671		
	0		
	0		
	(542,736)		
		0	
(542,736)			
	0		
	0		
			0
	(542,736)		
	(.11)		
	(.11)		

3-MOS

DEC-31-1997	APR-01-1997	JUN-30-1997
		0
	0	
	0	
	0	
	0	
	0	0
	0	
0		0
0		
	0	0
	0	0
0		
	812,549	
812,549		
	1,042,482	
1,042,482		
310,004		
	0	
38,207		
(578,144)		
	0	
(578,144)		
	0	
	0	
		0
	(578,144)	
	(.20)	
	(.20)	

6-MOS
DEC-31-1998
JAN-01-1998
JUN-30-1998
2,527,749
0
574,570
26,000
301,099
3,474,147
1,094,228
213,414
5,886,400
575,682
0
0
8,055,823
251,150
5,886,400
2,153,289
2,153,289
2,427,157
2,427,157
836,944
0
0
(1,082,321)
0
(1,082,321)
0
0
0
(1,082,321)
(.24)
(.24)

